Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-05-20
2008-05-20
Tsang, Cecilia J. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S001000, C434S007000
Reexamination Certificate
active
07375073
ABSTRACT:
The present invention describes the use of angiotensin-(1-7) peptide as an anti-cancer therapeutic. Thus, in one embodiment, the present invention comprises a composition to inhibit the growth of cancer cells in an individual comprising a pharmaceutically effective amount of an agonist for the angiotensin-(1-7) receptor to inhibit cancer cell growth or proliferation. Application of a pharmaceutically effective amount of angiotensin-(1-7) or angiotensin-(1-7) receptor agonist is associated with an increase in the expression of genes involved in tumor suppression, apoptosis, and/or cell cycle inhibition, and a decrease the expression of known oncogenes, protein kinases, and/or cell cycle progression genes. Cancers treated using the methods and compositions described herein include cancers having an angiotensin-(1-7) receptor, including, but not limited to, breast and lung cancer.
REFERENCES:
patent: 6235766 (2001-05-01), Heitsch et al.
patent: 6239109 (2001-05-01), Rodgers et al.
patent: 6429222 (2002-08-01), Heitsch et al.
patent: 6455500 (2002-09-01), Rodgers et al.
patent: 7122523 (2006-10-01), Rodgers et al.
patent: 2001/0018449 (2001-08-01), Heitsch et al.
patent: 2004/0176302 (2004-09-01), Rodgers et al.
patent: WO 99/40106 (1999-08-01), None
patent: WO 02/087504 (2002-11-01), None
patent: WO 03/039434 (2003-05-01), None
Parsons, Peptide Hormones, University Park Press, Jun. 1976, p. 1-7.
Online-Medical Dictionary. “Amino acid”. http://cancerweb.ncl.ac.uk/cgi-bin/omd?query=amino+acid. Nov. 13, 1997 (complete reference available online).
P. Ambuhl, et al. Effects of angiotensin analogues and angiotensin receptor antagonists on paraventricular neurones.Regul.Pept. 1992;38:111-120.
R. G. Appel. Mechanisms of atrial natiuretic factor-induced inhibition of rat mesangial cell mitogenesis.Am.J.Physiol. 1990;259:E312-E318.
Y. Asada, et al. Inhibitory effects of prostacyclin analogue, TFC-132, an aortic neointimal thickening in vivo and smooth muscle cell proliferation in vitro.Prostaglandins Leukot.Essen.Fatty Acids. 1994;51:245-248.
K. L. Barrett, et al., Advances in cytochemical methods for detection of apoptosis.J.Histochem.Cytochem. 2001;49:821-832.
I. F. Benter, et al. Cardiovascular actions of angiotensin-(1-7),Peptides. 1993;14:679-684.
I. F. Benter, et al. Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats.Am.J.Physiol.Heart.Circ.Physiol. 1995;269:H313-H319.
R. R. Britto, et al. Role of angiotensin-(1-7) in modulation of the baroreflex in renovascular hypertensive rats.Hypertension. 1997;30:549-556.
K. B. Brosnihan, et al. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide.Hypertension. 1996;27:523-528.
F. M. Bumpus, et al. Nomenclature for Angiotensin Receptors. A report of the nomenclature committee of the council for high blood presssure research.Hypertension. 1991;17:720-721.
R. M. Carey. Role of the angiotensin AT2receptor in blood pressure regulation and therapeutic implications.Am.J.Hypertens. 2001;14:98-102.
D. J. Campbell, et al. Nephrectomy, converting enzyme inhibition, and angiotensin peptides.Hypertension. 1993;22:513-522.
M. C. Chappell, et al. Identification of angiotensin-(1-7) in rat brain: evidence for differential processing of angiotensin peptides.J.Biol.Chem. 1989:264:16518-16523.
M. C. Chappell, et al. Characterization of angiotensin II receptor subtypes in pancreatic acinar AR42J cells.Peptides. 1995;16:741-747.
M. C. Chappell, et al. Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme.Hypertension. 1998;31:362-367.
M. C. Chappell, et al. Processing of angiotensin peptides by NG108-15 neuroblastoma X glioma hybrid cell line.Peptides. 1990;11:375-380.
M. C. Chappell, et al. Conversion of angiotensin I to angiotensin-(1-7) by thimet oligopeptidase (E.C.3.4.24.15) in vascular smooth muscle cells.J Vasc Biol Med. 1994;5:129-137.
C. E. Clay, et al. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells.Carcinogenesis. 1999:20:1905-1911.
S. J. Cook, et al., Inhibition by cAMP of Ras-dependent activation of Raf.Science. 1993;262:1069-1072.
H. Darius, et al. Effects of ciprostene on restenosis rate during therapeutic transluminal coronary angioplasty.Prostaglandins in the Cardiovascular System. 1992;305-311.
M. De Gasparo, et al. Proposed update of angiotensin receptor nomenclature.Hypertension. 1995;25:924-927.
A. DelliPizzi, et al. Natriuretic action of angiotensin(1-7).Br.J.Pharmacol. 1994;111:1-3.
A. DelliPizzi, et al. Renal actions of Ang-(1-7): Comparison with Ang II.The Pharmacologist34:196. 1992 (Abstract 326).
B. R. Dey, et al. Suppressor of cytokine signaling (SOCS)-3 protein interacts with the insulin-like growth factor-I receptor.Biochem.Biophys.Res.Commun. 2000;278:38-43.
R. J. Duhe, et al. Negative regulation of Janus kinases.Cell Biochem.Biophys. 2000; 34; 17-59.
D. Felix, et al. Neurophysiological responses to angiotensin-(1-7).Hypertension. 1991;17:1111-1114.
A. Fernandes, et al. ErbB-2 kinase is required for constitutive stat 3 activation in malignant human lung epithelial cells.Int.J.Cancer. 1999;83:564-570.
C. M. Ferrario, et al. Counterregulatory actions of angiotensin-(1-7).Hypertension. 1997;30:535-541.
M. A. P. Fontes, et al. Evidence that angiotensin-(1-7) plays a role in the central control of blood pressure at the ventro-lateral medulla acting through specific receptors.Brain Res. 1994:665:175-180.
E. J. Freeman, et al. Angiotensin-(1-7) [Ang-(1-7)] inhibits vascular smooth muscle growth.Hypertension. 22, 414. 1993.
E. J. Freeman, et al. Angiotensin-(1-7) inhibits vascular smooth muscle cell growth.Hypertension. 1996;28:104-108.
P. E. Gallagher, et al. Estrogen regulation of angiotensin-converting enzyme mRNA.Hypertension. 1999;33:323-328.
P. E. Gallagher, et al. Molecular mechanisms for inhibition of human lung cancer cell growth by angiotensin. Proceedings of American Cancer Research; 43:759; Abstract No. 3767 presented at 93rdAnnual Meeting Apr. 6-10, 2002, San Franciso.
B. Gao, et al. Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells.FEBS Lett. 2001;488:179-184.
N. H. Garcia, et al. Angiotensin 1-7 has a biphasic effect on fluid absorption in the proximal straight tubule,J.Am.Soc.Nephrol. 1994;5:1133-1138.
Garcia, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.Oncogene. 2001;20:2499-2513.
J. B. Gibbs. Anticancer drug targets: growth factors and growth factor signaling.J.Clin.Invest. 2000;105:9-13.
R. J. Gryglewski, et al. Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides.Prostaglandins. 1976;12:685-713.
R. K. Handa, et al. Renal actions of angiotensin-(1-7) in vivo and in vitro studies.Am.J.Physiol. 1996;270:F141-F147.
S. L. Hazen, et al. Suicide inhibition of canine myocardial cytosolic calcium-independent phospholipase A2; mechanism-based discrimination between calcium-dependent and—independent phospholipases A2.J.Biol.Chem. 1991;266:7227-7232.
L. E. Heasley. Autocrine and paracrine signaling through neuropeptide receptors in human cancer.Oncogene. 2001;20:1563-1569.
H. Heitsch, et al. Angiotensin-(1-7) stimulated release of nitric oxide and superoxide release from endolethial cells.Hypertension. 2001;37:72-76.
S. I. Hii, et al. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma.British Journal of Cancer. 1998;77:880-883.
S. D. Hitchey, et al. Association between the natriuretic action of angiotensin- (1-7) and selective stimulation of renal prostaglandin I2release.Hypertension. 1995;25:1238-1244.
W. C. Hope, et al. Secretory phospholipase A2inhibitors and calmodulin antagonists as inhibitors of cytosolic phospholipase A2.Agents Actions. 1993;39:C39-C42.
S. N. Iyer, et al. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan.Hypertension. 1998;31:699-705.
S. N. Iyer et al. Angiotens
Ferrario Carlos M.
Gallagher Patricia E.
Tallant E. Ann
Audet Maury
Kilpatrick & Stockton LLP
Tsang Cecilia J.
Wake Forest University Health Sciences
LandOfFree
Angiotensin-(1-7) and angiotensin-(1-7) agonists for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Angiotensin-(1-7) and angiotensin-(1-7) agonists for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Angiotensin-(1-7) and angiotensin-(1-7) agonists for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2808312